Resveratrol and Its Analogues – Is It a New Strategy of Anticancer Therapy?

Open access


Resveratrol (RSV) is one of the polyphenols - metabolites common in plants,however it does not occur in animals. It occurs mainly in grape skin (Vitisvinifera), peanuts (Arachis hypogeal) and in the roots of (Polygonumcupidatum) a traditional Chinese curative plant.

RSV has a preventive property against the most serious diseases of modern world such as cancer, neurodegenerative diseases and cardiovascular diseases. Due to pleiotropy, RSV is currently the main object of many research teams′ interest, which is shown by the significant number of publications devoted to this subject.

Animal and human conducted studies have shown very low bioavailability of RSV (approx. 2%), which is the result of rapid biotransformation to sulphate and to a lesser extent, to the glucuronide conjugates as well. The studies on the improvement of RSV bioavailability, which have beencarried out for many years, have contributed to the synthesis of the analogues of more chemopreventive and more desirable pharmacokinetic properties. In order to enhance antiproliferative activity and RSV bioavailability, series of methyl analogues were synthesized and this will be described later in more detail. An example of such a derivative is DMU-212 (3,4,4’5-tetramethoxystilbene).

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] Aldawsari SF Velazquez-Martinez CA. 34’5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency The Journal of New Anticancer Agents-Springer Science + Business Media New York 2015; doi:

    • Crossref
    • Export Citation
  • [2] Androutsopoulos VP Ruparelia KC Papakyriakou A Filippakis H TsatsakisAM Spandidos DA. Anticancer effects of the metabolic products of the resveratrol analogue DMU-212: structural requirements for potency Eur. J. Med. Chem. 2011; 46 (6): 2586-95.

  • [3] Belleri M Ribatti D Nicoli S Cotelli F Forti L Vannini V Stiva la LA Presta M. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 354’-trimethoxystibene Mol. Pharmcol. 2005; 67 (5): 1451-9.

  • [4] Berbee JF Wong MC Wang Y van der Hoorn JW Khedoe PP Dźwieku JB Mol IM Hiemstra PS Tsikas D Romijn JA. Resveratrol protects against atherosclerosis but does not add to the antiatherogenic effect of atorvastatin in APOE*3-Leiden.CETP mice J.Nutr.Biochem. 2013; 24 (8): 1423-30.

  • [5] Berta GN Salamone P. Sprio AE Di Scipio F. Marinos LM Sapino S. Carlotti ME Cavalli R. Di Carlo F. Chemoprevention of 712-dimethylbenz[a]anthracene (DMBA) - induced oral carcinogenesis in hamster cheekpouch by topical application of resveratrol complexed with 2-hydroxypropyl-betacyclodextrin Oral Oncol. 2010; 46 (1): 42-8.

  • [6] Bertelli AA Das DK. Gr apes wines r esver at r ol and heart healt h J. Cardiovasc. Pharmacol. 2009; 54: 468-476.

  • [7] Cardile V Chillemi R Lombardo L Sciuto S Spatafora C Tringali C. Antiproliferative activity of methylated analogues of E- and Z-resveratrol. Z. Naturforsch C. 2007; 62 (3-4): 189-95.

  • [8] Cardile V Lombardo L Spatafora C Tringali C. Chemo-enzymatic synthesis and cell-growth inhibition activity of resveratrol analogues Bioorganic Chemistry. 2005; 33 (1): 22-33.

  • [9] Chang TK Yeung RK. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5 Can J. Physiol. Pharmacol. 2001; 79 (3): 220-6.

  • [10] Cichocki M Baer-Dubowska W Wierzchowski M Murias M Jodynis-Liebert J. 3454’-trans-tetramethoxystilbene (DMU-212) modulates the activation of NF-ĸB AP-1 and STAT3 transcription factors in rat liver carcinogenesis induced by initiation-promotion regimen Mol Cell Biochem. 2014; 391 (1-2): 27-35.

  • [11] Colin D Gimazane A Lizard G. Izard JC Solary E Latruffe N Delmas D. Effects of resveratrol analogs on cell cycle progression cell cycle associated proteins and 5-fluorouracil sensitivity in human derived colon cancer cells Int. J. Cancer. 2009; 124 (12): 2780-8.

  • [12] Cucciolla V Borriello O Oliva A Galletti P Zappia V Ragione FD. Resveratrol:From Basic Science to the Clinic Cell Cycle 2007; 6 (20): 2495-2510.

  • [13] DEAK M FALK H. On the chemistry of resveratrol diastereomers Monat für Chem. 2003; 134: 883-888.

  • [14] Deng YH Alex D Huang HQ Wang N Yu N Wang YT Leung GP Lee SM. Inhibit ion of TNF-α- mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative trans-354’-trimethoxystilbene Phytother. Res. 2011; 25 (3): 451-7.

  • [15] Fulda S. Resveratrol and derivatives for the prevention and treatment of cancer Drug Discover Today. 2010; 15 (17-18): 757-765.

  • [16] Goldberg DM Yan J Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects Clin. Biochem. 2003; 36: 79-87.

  • [17] Harikumar KB Aggarwal BB. Resver atrol: a multitargeted agent for age-associated chronic diseases Cell Cycle. 2008; 7 (8): 1020-1037.

  • [18] Juan ME Pilar Vinardell M Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful Journal of Nutrition 2002; 132 (2): 257-260.

  • [19] Kang SY Lee JK Choi O Young Kim C Jang JH Hwang BY Hong YS. Biosynthesis of methylated resveratrol analogs through the construction of an artificial biosynthetic pathway in E.coli BMC Biotechnology 14: 67; Published online 17.07.2014; doi:

    • Crossref
    • Export Citation
  • [20] Kopeć A Piątkowska E Leszczyńska T Bieżanowska-Kopeć R. Prozdrowotne właściwości resweratrolu Nauka Technologia Jakość 2011; 5 (78): 5-15.

  • [21] Kumar A Negi G Sharma SS. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms Curr. Med. Chem. 2013; 20 (36): 4640-5.

  • [22] Lin HS Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in Sprague-dawley rats: the impacts of aqeous solubility dose escalation food and repeated dosing on oral bioavailability J. Pharm. Sci. 2011; 100 (10): 4491-500.

  • [23] Liu Yin MY Wy X Zeng M Zhao Q Keefe Liu DL. Resveratrol protects against age-associated infertility in mice Hum. Reprod. 2013; 28 (3): 707-717.

  • [24] MA Z MOLAVI O HADDADI A LAI R GOSSAGE RA LAVASANIFAR A. Resveratrol analog trans 3454’-tetramethoxystilbene(DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol Cancer Chemother. Pharmacol. 2008; 63 (1): 27-35.

  • [25] Mikstacka R Rimando AM Dutkiewicz Z Stefański T Sobiak S. Design synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1 CYP1A2 and CYP1B1 Bioorganic & Medicinal Chemistry 2012; 20 (17): 7117-5126.

  • [26] Okawara M Katsuki H Kurimoto E Shibata H Kume T. Akaike A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults Biochem. Pharmacol. 2007; 73: 550-560.

  • [27] Olas B. Resweratrol jako dobroczyńca w profilaktyce chorób układu krążenia Kosmos problemy nauk biologicznych 2006; 55 (2-3): 277-285.

  • [28] Ovesna Z Horvathova-Kozics K. Structure-activity relationship of trans-resveratrol and its analogues Neoplasma2005; 529 (6): 450-5.

  • [29] Park E-J Pezzuto JM. The pharmacology of resveratrol in animals and humans BBA-Molecular Basis of Disease 2015; 1852 (6): 1071-1113.

  • [30] PERVAIZ S. Resveratrol: from grapevines to mammalian biology FASEB J. 2003; 17: 1975-1985.

  • [31] Piotrowska H Myszkowski K Ziółkowska A Kulcenty K Wierzchowski M Kaczmarek M Murias M Kwiatkowska-Borowczyk E Jodynis-Liebert J. Resveratrol analogue 344’5-tetramethoxystilbene inhibits growth arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells Toxicol. Apppl. Pharmacol. 2012; 263 (1): 53-60.

  • [32] Potter GA Patterson LH Wanogho E Perry PJ Butler PC Ijaz T RupareliaKCLamb JH Farmer PB Stanley LA Burke MD. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B Br. J. Cancer 2002; 86: 774-778.

  • [33] Rahal K Schmiedlin-Ren P Adler J Dhanani M Sultani V Rittershaus AC Reingold L McKenna BJ Christman GM. Resveratrol has anti-inflammatory and antifibrotic effects in the peptidoglycan- polysaccharide rat model of Crohn’s disease Inflamm Bowel Dis. 2012; 18 (4): 613-23.

  • [34] Regev-Shoshani G Shoseyov O Bilkis I Kerem Z. Glycosylation of resveratrol protects it from enzymic oxidation Biochem.J. 2003; 374: 157-163.

  • [35] Roberti M Pizzirani D Simoni D Rondanin R Baruchello R Bonora C Buscemi F Grimaudo S Tolomeo M. Synthesis and biological evaluation of resveratrol and analogs as apoptosis-inducing agents J. Med. Chem. 2003; 46: 3546-3554.

  • [36] Sale S Tunstall RG Ruparelia KC Potter GA Steward WP Gescher AJ. Comparison of the effects of the chemopreventive agent resveratrol and its analog trans 3454’-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells Int. J. Cancer. 2005; 115 (2): 194-201.

  • [37] Sale S Verschoyle RD Boocock D Jones DJ.L Wilsher N Ruparelia KC Potter GA Farmer PB Steward WP Gescher AJ. Pharmacokinetics in miceand growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3454’-tetramethoxystilbene Br. J. Cancer 2004; 90 (3): 736-744.

  • [38] Schrauwen P Timmers S. Can resveratrol help to maintain metabolic helath? Proc. Nut.r Soc. 2014; 73 (2): 271-7.

  • [39] Simoni D Roberti M Invidiata FP Aiello E Aiello S Marchett P. Stilbene-based anticancer agents: Resveratrol analogues active toward HL-60 leukemic cells with a non-specific phas mechanism. Bioorg. Med. Chem. Lett. 2006; 16 (12): 3245-3248.

  • [40] Singh N Agrawal M Dore S. Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models. ACS Chem. Neurosci. 2013; 4 (8): 1151-1162.

  • [41] Sun X. Measurement and correlation of stability of trans-resveratrol in 11 solvents at T=(2782 288.2 298.2 and 318.2) K. J. Chem. Thermodynamics 2008; 40: 735- 738.

  • [42] Szaefer H Cichocki M Majchrzak-Celińska A. Nowe cytochromy P450 jako biomarkery i potencjalne cele oddziaływania w chemio prewencji i terapii nowotworów PostepyHig. Med. Dosw. (online) 2013; 67: 709-718.

  • [43] Udenigwe CC Ramprasath VR Aluko RE. Jones P.JH. Potential of resveratrol in anticancer and anti- -inflammatory therapy Nutrition Reviews 2008; 66 (8): 445-454.

  • [44] Waffo-Teguo P Hawthorne ME Cuendet M Merillon JM Kinghorn AD Pezzuto JM Mehta RG. Potential cancer - chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitisvinifera) cell cultures Nutr. Cancer. 2001; 40: 173.

  • [45] Wenezel E Somoza V. Metabolism and bioavailability of trans-resveratrol Mol.Nutr.Food Res. 2005; 49: 472-481.

  • [46] You-QiuXue Jin-Ming Di Yun Luo Ke-Jun Cheng Xing Wei Zhi Shi. Resveratrol oligomers for prevention and treatment of cancers Oxid Med Cell Longev. 2014 Published online 2014 March 23.

  • [47] Yu C Shin YG Kosmeder JW Pezzuto JM van Breemen RB. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate Rapid Commun. Mass Spectrom. 2003; 17 (4): 307-13.

  • [48] Zdrojewicz Z Belowska-Bień K. Resweratrol - działanie i znaczenie kliniczne Adv. Clin. Exp. Med. 2005; 14 (5): 1051-1056.

Journal information
Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 505 424 3
PDF Downloads 236 210 2